Narcolepsy Therapeutics Market - A Global and Country Level Analysis: Focus on Therapeutics, Indication, Product, and Country - Analysis and Forecast, 2022-2032

1.1 Product Definition
1.2 Inclusion and Exclusion

2.1 Key Questions Answered in the Report

3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling

4.1 Introduction
4.2 Epidemiology of Narcolepsy
4.2.1 U.S.
4.2.2 EU4 and U.K.
4.2.3 Japan
4.3 Key Therapeutic Classes for Narcolepsy
4.3.1 Central Nervous System Stimulants
4.3.2 Histamine-3 (H3) Receptor Antagonist/Inverse Agonist
4.3.3 Dopamine and Norepinephrine Reuptake Inhibitor (DNRI)
4.4 Currently Approved and Investigational Treatments for Narcolepsy
4.5 Current Market Size and Growth Potential, $Million, 2021-2031

5.1 Overview
5.2 Treatment Guideline for Narcolepsy Therapeutics
5.3 Legal Requirements and Frameworks
5.3.1 Legal Requirement and Framework in the U.S.
5.3.1.1 Clinical Trial Authorization
5.3.1.2 Marketing Authorization
5.3.1.3 USFDA Guidelines for NDA Submission
5.3.1.4 Post Authorization Regulations
5.3.2 Legal Requirement and Framework in Europe
5.3.2.1 EMA Drug Licence Application Process
5.3.2.2 Centralized Procedure
5.3.2.3 Decentralized Procedure
5.3.2.4 Mutual-Recognition Procedure
5.3.2.5 National Procedure
5.3.3 Legal Requirements and Frameworks in Japan
5.4 Reimbursement Scenario

6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Large Population of Undiagnosed and Untreated Narcolepsy Patients
6.3.2 Increasing Research Funding for Neuroscience
6.3.3 Approval of Advanced Therapies with Novel Mechanism of Action (MoA)
6.3.4 Existing Unmet Needs of Patients and Healthcare Professionals (HCPs)
6.4 Market Restraints
6.4.1 Delayed Diagnosis
6.4.2 Lack of Awareness
6.5 Market Opportunities
6.5.1 Growing Opportunities in Asian Countries
6.5.2 Opportunity for Narcolepsy Therapies with Novel Composition and Route of Administration

7.1 Corporate Strategies
7.1.1 Synergistic Activities
7.1.2 Mergers and Acquisitions
7.1.3 Funding and Business Expansion Activities
7.2 Business Strategies
7.2.1 Regulatory and Legal Developments
7.2.2 Clinical Developments

8.1 Overview
8.2 Commercialized Products
8.2.1 Xywav
8.2.2 Sunosi
8.2.3 Wakix
8.3 Pipeline Products
8.3.1 Phase 1
8.3.2 Phase 2
8.3.2.1 SUVN-G3031
8.3.2.2 Quilience
8.3.3 Phase 3
8.3.3.1 AXS-12
8.3.3.2 FT218

9.1 Overview
9.2 Type 1 Narcolepsy
9.3 Type 2 Narcolepsy
9.4 Secondary Narcolepsy

10.1 Overview
10.2 Central Nervous System Stimulant
10.3 Norepinephrine Reuptake Inhibitor
10.4 Histamine-3 (H3) Receptor Antagonist/Inverse Agonist

11.1 Overview
11.2 U.S.
11.3 U.K.
11.4 Germany
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan

12.1 Overview
12.2 Jazz Pharmaceuticals PLC
12.2.1 Company Overview
12.2.2 Role of Jazz Pharmaceuticals PLC in the Global Narcolepsy Therapeutics Market
12.2.3 Key Competitors
12.2.4 Key Distributors
12.2.5 Financials
12.2.6 Corporate Strategies
12.2.7 Analyst’s Perspective
12.3 Harmony Bioscience, LLC
12.3.1 Company Overview
12.3.2 Role of Harmony Biosciences, LLC in the Global Narcolepsy Therapeutics Market
12.3.3 Key Competitors
12.3.4 Key Distributors
12.3.5 Financials
12.3.6 Corporate Strategies
12.3.7 Analyst’s Perspective
12.4 Axsome Therapeutics, Inc.
12.4.1 Company Overview
12.4.2 Role of Axsome Therapeutics, Inc. in the Global Narcolepsy Therapeutics Market
12.4.3 Key Competitors
12.4.4 Financials
12.4.5 Corporate Strategies
12.4.6 Analyst’s Perspective
12.5 Avadel Pharmaceuticals PLC
12.5.1 Company Overview
12.5.2 Role of in Avadel Pharmaceuticals PLC in the Global Narcolepsy Therapeutics Market
12.5.3 Key Competitors
12.5.4 Key Distributors
12.5.5 Financials
12.5.6 Corporate Strategies
12.5.7 Analyst’s Perspective
12.6 Takeda Pharmaceutical Co Ltd
12.6.1 Company Overview
12.6.2 Role of Takeda Pharmaceutical Co Ltd in the Global Narcolepsy Therapeutics Market
12.6.3 Key Competitors
12.6.4 Key Distributors
12.6.5 Financials
12.6.6 Corporate Strategies
12.6.7 Analyst’s Perspective
12.7 Sumitomo Pharma Co Ltd
12.7.1 Company Overview
12.7.2 Role of Sumitomo Pharma Co Ltd in the Global Narcolepsy Therapeutics Market
12.7.3 Key Competitors
12.7.4 Key Distributors
12.7.5 Financials
12.7.6 Corporate Strategies
12.7.7 Analyst Perspectives
12.8 Suven Life Sciences Limited
12.8.1 Company Overview
12.8.2 Role of Suven Life Sciences Limited in the Global Narcolepsy Therapeutics Market
12.8.3 Key Competitors
12.8.4 Financials
12.8.5 Corporate Strategies
12.8.6 Analyst Perspectives
12.9 NLS Pharmaceutics AG
12.9.1 Company Overview
12.9.2 Role of NLS Pharmaceutics AG in the Global Narcolepsy Therapeutics Market
12.9.3 Key Competitors
12.9.4 Financials
12.9.5 Corporate Strategies
12.9.6 Analyst’s Perspective
12.1 Balance Therapeutics
12.10.1 Company Overview
12.10.2 Role of Balance Therapeutics in the Global Narcolepsy Therapeutics Market
12.10.3 Key Competitors
12.10.4 Corporate Strategies
12.10.5 Analyst’s Perspective

Figure 1: Global Narcolepsy Therapeutics Market Dynamics
Figure 2: Global Narcolepsy Therapeutics Market (by Indication), $Million, 2021 and 2032
Figure 3: Global Narcolepsy Therapeutics Market (by Therapeutics), $Million, 2021 and 2032
Figure 4: Global Narcolepsy Therapeutics Market (by Country), $Million, 2021-2032
Figure 5: Global Narcolepsy Therapeutics Market Segmentation
Figure 6: Global Narcolepsy Therapeutics Market Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Epidemiology-Based Market Sizing and Forecasting Methodology
Figure 9: Symptoms of Narcolepsy
Figure 10: Impact of Narcolepsy on Day-to-Day Activities
Figure 11: Prevalence, Diagnosed Population, and Diagnosed and Treated Population of Narcolepsy in the U.S., 2021-2032
Figure 12: Estimated Population of Narcolepsy in EU-4 and U.K., 2021
Figure 13: Existing Treatment Options for Managing Excessive Daytime Sleepiness (EDS) and Cataplexy in Type 1 Narcolepsy
Figure 14: Global Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 15: U.S. Narcolepsy Treatment Guideline
Figure 16: European Narcolepsy Treatment Guideline
Figure 17: Clinical Trial Authorization for Narcolepsy Therapeutics in the U.S.
Figure 18: Steps for Obtaining Marketing Authorization
Figure 19: U.S. FDA Review Timeline
Figure 20: EMA Review Timeline
Figure 21: Market Dynamics
Figure 22: Impact Analysis
Figure 23: Narcolepsy Patients: Undiagnosed, Diagnosed and Treated, Diagnosed and Untreated
Figure 24: Neuroscience Research Funding (2013-2022)
Figure 25: Recently Approved Narcolepsy Products
Figure 26: Narcolepsy Therapeutics Unmet Needs: Patients and HCPs' Perspective
Figure 27: Market Restraints: Delayed Diagnosis
Figure 28: Advanced Narcolepsy Therapies
Figure 29: Share of Key Developments and Strategies, January 2019-May 2022
Figure 30: Synergistic Activities Share (by Company), January 2019-May 2022
Figure 31: Funding and Business Expansion Activities (by Company), January 2019-May 2022
Figure 32: Regulatory and Legal Developments (by Company), January 2019-May 2022
Figure 33: Regulatory and Legal Developments (by Company), January 2019-May 2022
Figure 34: Current Narcolepsy Treatment
Figure 35: Share of Global Narcolepsy Therapeutics Market (by Product), $Million, 2021 and 2032
Figure 36: Global Narcolepsy Therapeutics Market (by Commercialized Product)
Figure 37: Xywav Concept to Launch
Figure 38: Xywav U.S. Prescribing Information
Figure 39: Xywav Adoption and Awareness in the U.S.
Figure 40: Global Narcolepsy Therapeutics Market (Xywav), $Million, 2021-2032
Figure 41: Xywav Recent Development Key Takeaways
Figure 42: Sunosi Development and Launch Timeline in the U.S.
Figure 43: Sunosi’s Strong Market Access Position
Figure 44: Global Narcolepsy Therapeutics Market (Sunosi), $Million, 2021-2032
Figure 45: Wakix Development Timeline
Figure 46: Wakix Favorable Benefit Profile Key Features
Figure 47: Healthcare Professional and Patient Research Key Findings, 2021
Figure 48: Global Narcolepsy Therapeutics Market (Wakix), $Million, 2021-2032
Figure 49: Global Narcolepsy Therapeutics Market (by Pipeline Product)
Figure 50: Recent Developments and Key Milestones in TAK-925 and TAK-861 Phase 1 Trial
Figure 51: Global Narcolepsy Therapeutics Market (SUVN-G3031), $Million, 2021-2032
Figure 52: Quilience’s Distinctive Competitive Advantages
Figure 53: Global Narcolepsy Therapeutics Market (SUVN-G3031), $Million, 2021-2032
Figure 54: Global Narcolepsy Therapeutics Market (AXS-12), $Million, 2021-2032
Figure 55: FT218 Regulatory Timeline in U.S.
Figure 56: Global Narcolepsy Therapeutics Market (FT218), $Million, 2021-2032
Figure 57: Global Narcolepsy Therapeutics Market (by Indication)
Figure 58: Share of Global Narcolepsy Therapeutics Market (by Indication), $Million, 2021 and 2032
Figure 59: Global Narcolepsy Therapeutics Market (Type 1 Narcolepsy), $Million, 2021-2032
Figure 60: Global Narcolepsy Therapeutics Market (Type 2 Narcolepsy), $Million, 2021-2032
Figure 61: Global Narcolepsy Therapeutics Market (Secondary Narcolepsy), $Million, 2021-2032
Figure 62: Global Narcolepsy Therapeutics Market (by Therapeutics), $Million, 2021 and 2032
Figure 63: Global Narcolepsy Therapeutics Market (Central Nervous System Stimulant), $Million, 2021-2032
Figure 64: Global Narcolepsy Therapeutics Market (Norepinephrine Reuptake Inhibitor), $Million, 2021-2032
Figure 65: Global Narcolepsy Therapeutics Market (Histamine-3 (H3) Receptor Antagonist/Inverse Agonist), $Million, 2021-2032
Figure 66: Global Narcolepsy Therapeutics Market (by Country), $Million, 2021-2032
Figure 67: Market Dynamics of U.S. Narcolepsy Therapeutics Market
Figure 68: U.S. Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 69: Market Dynamics of U.K. Narcolepsy Therapeutics Market
Figure 70: U.K. Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 71: Market Dynamics of Germany Narcolepsy Therapeutics Market
Figure 72: Germany Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 73: Market Dynamics of France Narcolepsy Therapeutics Market
Figure 74: France Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 75: Market Dynamics of Italy Narcolepsy Therapeutics Market
Figure 76: Italy Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 77: Market Dynamics of Spain Narcolepsy Therapeutics Market
Figure 78: Spain Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 79: Market Dynamics of Japan Narcolepsy Therapeutics Market
Figure 80: Japan Narcolepsy Therapeutics Market, $Million, 2021-2032
Figure 81: Total Number of Companies Profiled
Figure 82: Jazz Pharmaceutical PLC: Product Portfolio
Figure 83: Jazz Pharmaceuticals PLC: Overall Financials, 2019-2021
Figure 84: Jazz Pharmaceuticals PLC: Revenue (by Business Segment), 2019-2021
Figure 85: Jazz Pharmaceuticals PLC: Revenue (by Region), 2019-2021
Figure 86: Jazz Pharmaceutical PLC: R&D Expenditure, 2019-2021
Figure 87: Harmony Biosciences, LLC.: Product Portfolio
Figure 88: Harmony Biosciences, LLC: Overall Financials, 2019-2021
Figure 89: Harmony Biosciences, LLC: R&D Expenditure, 2019-2021
Figure 90: Axsome Therapeutics, Inc.: Pipeline Product
Figure 91: Axsome Therapeutics, Inc.: R&D Expenditure, 2019-2021
Figure 92: Axsome Therapeutics, Inc.: R&D Expenditure (AXS-12), 2019-2021
Figure 93: Regulatory Timeline of FT218
Figure 94: Avadel Pharmaceuticals PLC: Product Portfolio
Figure 95: Avadel Pharmaceuticals PLC: Overall Financials, 2019-2021
Figure 96: Avadel Pharmaceuticals PLC: R&D Expenditure, 2019-2021
Figure 97: Takeda Pharmaceutical Co Ltd: Product Portfolio
Figure 98: Takeda Pharmaceutical Co Ltd: Overall Financials, 2019-2021
Figure 99: Takeda Pharmaceutical Co Ltd: Revenue (by Business Segment), 2019-2021
Figure 100: Takeda Pharmaceutical Co Ltd: Revenue (by Region), 2019-2021
Figure 101: Takeda Pharmaceutical Co Ltd: R&D Expenditure, 2019-2021
Figure 102: Sumitomo Pharma Co Ltd: Product Portfolio
Figure 103: Sumitomo Pharma Co Ltd: Overall Financials, 2019-2021
Figure 104: Sumitomo Pharma Co Ltd: Revenue (by Business Segment), 2019-2021
Figure 105: Sumitomo Pharma Co Ltd: Revenue (by Region), 2019-2021
Figure 106: Sumitomo Pharma Co Ltd: R&D Expenditure, 2019-2021
Figure 107: Suven Life Sciences Limited: Product Portfolio
Figure 108: Suven Life Sciences Limited: Overall Financials, 2019-2021
Figure 109: Suven Life Sciences Limited: R&D Expenditure, 2019-2021
Figure 110: NLS Pharmaceutics AG: Product Portfolio
Figure 111: NLS Pharmaceutics AG: R&D Expenditure, 2019-2021
Figure 112: Balance Therapeutics: Product Portfolio

Table 1: Recently Marketed and Pipeline Therapies for the Treatment of Narcolepsy
Table 2: Market Status of Commercialized and Pipeline Therapies
Table 3: Current Therapies Available for the Treatment of Narcolepsy
Table 4: Investigational Therapies for the Treatment of Narcolepsy
Table 5: Narcolepsy Therapeutics Coverage
Table 6: Narcolepsy Treatment Recommendation by American Academy of Sleep Medicine clinical
Table 7: Most Common Symptoms in Narcolepsy
Table 8: Key Marketed and Pipeline Central Nervous System Stimulants
Table 9: Key Marketed and Pipeline Norepinephrine Reuptake Inhibitors
Table 10: Key Marketed and Pipeline Histamine-3 (H3) Receptor Antagonist/Inverse Agonist
Table 11: Key Marketed and Pipeline Products in the U.S.
Table 12: Key Marketed and Pipeline Products in the U.K.
Table 13: Key Marketed and Pipeline Products in Germany
Table 14: Key Marketed and Pipeline Products in France
Table 15: Key Marketed and Pipeline Products in Italy
Table 16: Key Marketed and Pipeline Products in Spain
Table 17: Jazz Pharmaceutical PLC: Key Competitors
Table 18: Harmony Biosciences, LLC: Key Competitors
Table 19: Axsome Therapeutics, Inc.: Key Competitors
Table 20: Avadel Pharmaceuticals PLC: Key Competitors
Table 21: Takeda Pharmaceutical Co Ltd: Key Competitors
Table 22: Sumitomo Pharma Co Ltd: Key Competitors
Table 23: Suven Life Sciences Limited: Key Competitors
Table 24: NLS Pharmaceutics AG: Key Competitors
Table 25: Balance Therapeutics: Key Competitors